New Studies suggests " which is more relevant to reduce risk of venous thromboembolism: Estradiol transdermal system or estrogen contraceptive pills "

Pharma Admission

Pharma courses

pharma admission

pharma courses

A New studies suggested a new hormonal therapy to reduce risk of venous thromboembolism than oral estrogen-only hormone therapy agents (contraceptive pills). In this study they compared Estradiol transdermal system with oral estrogen hormone therapy.

It is known that Estrogens are induce synthesis of clotting factors ( factors II, VII, IX and X ) which tends to increase in blood coagulability. Also other reasons are available for that.

The study, of 27,000 women who used transdermal replacement therapy and 27,000 matched controls taking estrogen orally and the mean age of was 48.9 years; in each 6,044 and 1,788 participants had a hysterectomy and an oophorectom respectively found that those who used estrogen patches were one-third less likely to develop deep vein thrombosis or pulmonary embolism.

A total of 115 estradiol transdermal system users developed venous thromboembolism, compared with 164 women in the oral estrogen hormone therapy. This report was published in menopause.



Latest News